【协办】BioVerse episode 08 - Recap of AACR2024

汇聚群英智慧，闪亮你我星光

Together, Spark Biomedicine!

Join Bioverse webinar episode 8 to review the exciting presentations from AACR 2024 in San Diego. Our experts of cancer research and drug development will discuss:

• The industry-shaping data of ADC and radiopharmaceutical

• Clinical data from cell therapy, bispecific antibody, cancer vaccine, targeted therapy, and other drug classes

• Novel targets and industry-shaping scientific breakthroughs

• Practice-changing or market-moving clinical trial data

• Highlights of presentations from Asian biotech companies

Event details

主题：BioVerse episode 08 - Recap of AACR2024

时间: 2024年4月11日 Thur 9:00 AM（EST）/ 2024年4月11日 周四  9:00 PM（北京时间）

地点: zoom meeting（扫描二维码获得zoom注册链接或点击文末“阅读原文”）

Speakers intro

Lihua Yu, PhD

As LifeMine’s Chief Data Officer, Lihua brings vast experience in drug discovery from target identification to translational medicine, data science, and early clinical development. Lihua is passionate about integrating and applying data science across R&D, partnering with all functions to drive the platform and pipeline forward.

Lihua comes from Fog Pharma where she was leading the Data Science function and co-leading the discovery platform and new targets. Prior to Fog, Lihua was at H3 where she first served at head of bioinformatics, later as Chief Data Science officer and President. Preceding H3, Lihua was the cancer bioinformatics leader at AstraZeneca Oncology US.

Lihua holds a Ph.D. in biomedical engineering from Boston University, studying under Dr. Temple Smith, and M.E. and B.E. in biomedical engineering from Tsinghua University in Beijing, China.

Cassian Yee, MD

Dr. Yee is a Professor in the Division of Cancer Medicine, Director of the Program in TCR-based Therapeutics and Co-Director of the Adoptive Cellular Therapy Platform at UT MD Anderson Cancer Center. 

He is an elected member of the American Society of Clinical Investigator, former co-Leader of the Stand Up to Cancer- AACR/CRI Dream Team and recipient of Damon Runyon Cancer Research Foundation Physician Scientist award,  and the Rao Potul Basic Science Award.  He holds an endowed position as the Kenneth Muller Professorship of Melanoma Research. Over the last 20+ years, Dr. Yee has pioneered a form of ACT, known as Endogenous T Cell (ETC) therapy, using peripheral blood to generate a uniform population of antigen-specific memory T cells. He has conceived and executed several IND-approved first-in-human clinical studies establishing principles of T cell persistence, memory and antigen-spreading He is corresponding or lead author in > 80 publications, including The New England Journal of Medicine, Nature, Science, Science Immunology, Science Translational Medicine, Nature Medicine, Journal of Clinical Oncology, Journal of Experimental Medicine, Gastroenterology and Cancer Immunology Research. He holds > 15 worldwide patents on ex vivo generation of antigen specific T cells, memory reprogramming, and antigen discovery and  seeks to extend immunotherapy-based cancer treatments globally. 

He is scientific co-founder of Immatics US and is the founder of Mongoose Bio, an early stage cell therapy company poised to treat patients with gastric, esophageal, lung , breast bladder, ovarian, uterine and other cancers. 

Jeff Bockman, PhD

Jeff leads the Oncology and Virology Practices at Lumanity. Jeff has extensive commercial and strategic perspective on the pharmaceutical and biotech industries. He has directed hundreds of in-depth licensing opportunity and valuation assessments during his tenure at Cello Health BioConsulting, now Lumanity. He often speaks at conferences on scientific and commercial issues in cancer, especially immuno-oncology.

Before joining Cello Health BioConsulting, Jeff was a Senior Research Scientist and Research Project Leader in the commercial development of oligonucleotide therapeutics for viral diseases and cancer at Innovir Laboratories; and an Assistant Research Professor at The George Washington University School of Medicine. He has worked closely with two Nobel Prize recipients – Dr. Sidney Altman on ribozymes, and Dr. Stanley Prusiner on prions – and holds four patents in the use of ribozymes.

He received a BA from University of California at San Diego, a PhD in Medical Microbiology from the University of California at Berkeley, and an MA in English/Creative Writing from New York University.

Jeff is a member of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the American Society of Gene and Cell Therapy (ASGCT), the Society for Immunotherapy of Cancer (SITC) and the New York Academy of Sciences (NYAS).

Jeff is a mentor for the NCI Innovation Conference, a judge for the Citeline Awards, an advisor to the JPM Biotech Showcase, a member of the Advisory "Group" to Skipper Bio Med (a preclinical research consultancy that provides pro bono services to academic and industry groups, developing promising lung and/or pancreatic cancer therapeutics/device. Skipper is fully supported by a private US family that has been personally impacted by these cancers and is committed to bridging the research “valley of death”).

Jeff is also part of the Clinical Advisory Board of ImmunOS (an immunotherapy company based in Zurich) and the Scientific Advisory Board of hC Bioscience (a novel RNA-based platform company in Cambridge, MA).

Leon ‘Jun’ Tang, PhD  

(BioVerse webinar host)

Leon ‘Jun’ Tang, is the founding partner of InScienceWeTrust BioAdvisory, a business development company focused on the East-West cross-border partnerships in the pharmaceutical industry. Dr. Tang is also the founder of InScienceWeTrust Community, which has more than 2,000+ members from Asian biotech community. He is also the c-founder and host of Bioverse webinar.

Dr. Tang serves as a scientific advisor to Mianus Capital, a boutique US-based healthcare PE/VC fund currently focused on ophthalmology. He is also an advisor to BioSpark, an Asian biotech professional’s association based in Massachusetts.

Previously, Dr. Tang was a senior director of BD Search & Evaluation at Shanghai Henlius Biotech, a public biotech listed on Hong Kong Stock Exchange, a biotech sell-side analyst at Barclays Investment Bank, and a senior manager/senior analyst at the philanthropic venture fund of Cancer Research Institute of New York.

Dr. Tang has published 50+ academic papers, some of which are in Nature Reviews Drug Discovery, Lancet Oncology, Science Translational Medicine, Nature Communications, Science Advances, PNAS, etc. Dr. Tang received his bachelor’s degree from Tianjin University, master’s degree from Nankai University, PhD from Icahn School of Medicine of Mount Sinai, and postdoctoral training at Memorial Sloan Kettering Cancer Center. 

Organizer

Partner &Collaborators

About us

BioSpark

BioSpark Group成立于2019年8月，是在美国麻省注册的非盈利机构。BioSpark致力于推动生命科学领域的高级人才交流，建立富有合作和互助精神的社群生态环境，实现学术和企业的跨界交流及思想碰撞，从而帮助华人科学家在世界生物医药领域提升领导力、开拓企业家精神及促进科学发现的商业转化。

BioSpark Group is a non-profit corporation registered in Massachusetts of the United States. The purpose of BioSpark Group is to establish a biotechnology ecosystem with a collaborative and supportive scholar network, promote leadership and entrepreneurship, and facilitate scientific translation.

Follow us on Twitter: 
https://twitter.com/BioSpark_Group

Follow us on LinkedIn: 
https://www.linkedin.com/company/biospark-group

BioSpark events Calendar: 
https://tinyurl.com/tcwy44t6

Email us: [e-mail]

合作或加入日常活动交流群，请添加小助手微信号：BioSpark-Group

 赞 助  机   构 

 战 略  合   作 

BioSpark Group致力于建立华人在生物医领域的生态系统和互助网络，立足于波士顿，我们在硅谷和中国与LEAP Initiative、Dahshu和医药笔记达成战略合作。

更多精彩，请关注BioSpark公众号